A 42-year-old woman with severe erythrodermic psoriasis covering >80% of body surface area, with fever and systemic symptoms, requires urgent systemic therapy. She has no contraindications to any agent. Which drug is the preferred choice for rapid disease control in this life-threatening presentation?

Explanation

## Cyclosporine: First-Line for Severe & Erythrodermic Psoriasis **Key Point:** Cyclosporine is the drug of choice for severe, rapidly progressive, and erythrodermic psoriasis because of its rapid onset of action (1–2 weeks) and potent immunosuppression, making it ideal for life-threatening presentations. ### Mechanism of Action Cyclosporine is a calcineurin inhibitor that blocks T-cell activation by preventing dephosphorylation of NFAT (nuclear factor of activated T cells), thereby suppressing IL-2 and other pro-inflammatory cytokines. ### Pharmacokinetics & Dosing - **Starting dose:** 3–5 mg/kg/day in divided doses (oral) - **Onset:** 1–2 weeks (fastest among systemic agents) - **Peak effect:** 8–12 weeks - **Maintenance:** 2–3 mg/kg/day after initial response - **Duration:** Usually limited to 12–16 weeks to minimize toxicity ### Why Cyclosporine in Erythrodermic Psoriasis 1. **Rapid onset:** Controls systemic inflammation and fever within days 2. **Potent immunosuppression:** Effective in severe, fulminant disease 3. **No teratogenicity:** Safe in women of childbearing age (unlike acitretin) 4. **Suitable for acute exacerbations:** Bridging therapy while awaiting MTX effect **High-Yield:** Cyclosporine is the only systemic agent with onset fast enough (1–2 weeks) to manage erythrodermic psoriasis and psoriatic exfoliative dermatitis acutely. ### Monitoring & Safety Concerns - **Baseline:** BP, renal function (creatinine, eGFR), LFTs, K^+^, Mg^2+^ - **Every 2 weeks initially, then monthly:** BP, renal function, electrolytes - **Major adverse effects:** - Hypertension (30–50% of patients) - Nephrotoxicity (dose-dependent, reversible if caught early) - Hyperkalemia - Gingival hyperplasia - Increased infection risk - Malignancy (with prolonged use >1 year) **Clinical Pearl:** Baseline serum creatinine should be <1.4 mg/dL. A rise >30% from baseline or development of hypertension mandates dose reduction or discontinuation. ### Comparison with Alternatives in Severe Disease | Agent | Onset | Efficacy in Erythroderma | Safety Concern | Duration | |-------|-------|--------------------------|----------------|----------| | **Cyclosporine** | 1–2 weeks | Excellent | HTN, nephrotoxicity | 12–16 weeks | | Methotrexate | 4–8 weeks | Good | Hepatotoxicity, marrow suppression | Long-term | | Acitretin | 8–12 weeks | Good | Teratogenicity, hyperlipidemia | Long-term | | Infliximab | 2–4 weeks | Excellent | TB reactivation, serious infections | Long-term | **Mnemonic for Cyclosporine Monitoring:** **"CHAMP"** — **C**reatinine, **H**ypertension, **A**cute rejection (graft), **M**agnesium/Potassium, **P**erfusion (renal). [cite:Griffiths & Barker Rook's Textbook of Dermatology 9e Ch 35; Kang & Krueger J Am Acad Dermatol 2017]